New York, NYNCT07531511Now EnrollingIRB Ready

SLC6A1 Neurodevelopmental Disorder (NDD) Clinical Trial in New York, NY

Access cutting-edge slc6a1 neurodevelopmental disorder (ndd) treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by UCB Biopharma SRL

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access slc6a1 neurodevelopmental disorder (ndd) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related slc6a1 neurodevelopmental disorder (ndd) treatment provided free

Apply for This New York Location

Check if you qualify for this slc6a1 neurodevelopmental disorder (ndd) clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This SLC6A1 Neurodevelopmental Disorder (NDD) Study in New York

The overall objective of this prospective longitudinal natural history study is to collect clinical data to characterize and evaluate the natural course of SLC6A1-NDD and assess the feasibility of certain assessments for the purpose of conducting future clinical studies in patients with this disease.

Sponsor: UCB Biopharma SRL

Who Can Participate

Inclusion Criteria

Patient with a diagnosis of SLC6A1-NDD characterized by epilepsy, global developmental delay, autism spectrum disorder, or intellectual disability, with a documented history of an SLC6A1 mutation, defined as pathogenic or likely pathogenic by the Investigator.
Patients should not be older than 17 years at time of assent/consent.
Patients under the age of 18 years with legal guardians providing informed consent. Assent will be obtained from any patients judged to have sufficient capacity to provide assent at the discretion of the Investigator.
Patient and patient's caregiver are willing and able to comply with study requirements (including diary completion and visit schedule).

Exclusion Criteria

Patients and their caregivers are unable to complete follow-up visits.
Patients with a history of an alternate diagnosis for disease, including a genetic cause, which is known to contribute to epilepsy or NDD.
Patient is currently receiving an investigational product(s) other than 4-phenylbutyrate or has received an investigational product within 30 days or within \<5 times the half-life of the investigational product, whichever is longer, prior to the Enrollment Visit.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07531511) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

SLC6A1 Neurodevelopmental Disorder (NDD) Treatment Options in New York, NY

If you're searching for slc6a1 neurodevelopmental disorder (ndd) treatment options in New York, NY, this clinical trial (NCT07531511) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced slc6a1 neurodevelopmental disorder (ndd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all slc6a1 neurodevelopmental disorder (ndd) clinical trials near you to find additional studies recruiting in your area.

More Developmental Delays Trials in New York, NY

See all developmental delays clinical trials recruiting in New York — not just this study.

Browse Developmental Delays Trials in New York →

Browse More Trials by Condition

Developmental Delays TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY